title: [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
abstract: Transfusion of labile blood products (red cell concentrates, platelet concentrates and plasma) is vital in the absence of alternatives. Patients and doctors have always feared infections transmitted by blood, blood components and blood-derived drugs. It is potentially dangerous to delay implementation of pathogen inactivation in labile blood products pending a perfect process. Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety.
authors: l'Académie nationale de médecine. Etablissement Français du Sang-Alsace, UMR_S949 INSERM-Université de Strasbourg, Strasbourg, France. jeanpierre.cazenave@efs-alsace.fr
authors: Jean-Pierre
authors: JP
authors: Cazenave
mesh_terms: D058731:Blood Safety / Q000379:methods* / Q000639:trends*; D001803:Blood Transfusion / Q000379:methods / Q000592:standards* / Q000706:statistics & numerical data; D017848:Blood-Borne Pathogens / Q000302:isolation & purification; D018562:Disease Transmission, Infectious / Q000517:prevention & control / Q000706:statistics & numerical data; D014943:Global Health; D019983:Guideline Adherence; D006284:Health Plan Implementation; D006801:Humans; D007391:International Cooperation; D050296:Microbial Viability; D065227:Transfusion Reaction